Soluble CD4 and CD4 immunoglobulin-selected HIV-1 variants: a phenotypic characterization

Area of Science:

• Virology
• Immunology
• Molecular Biology

Background:

• Human Immunodeficiency Virus type 1 (HIV-1) entry relies on interactions between its envelope glycoprotein gp120 and the CD4 receptor on host cells.
• Soluble CD4 (sCD4) and bivalent CD4-Ig are potential therapeutic agents designed to block HIV-1 entry by mimicking the cellular CD4 receptor.

Purpose of the Study:

• To investigate the mechanisms by which HIV-1 develops resistance to neutralization by monovalent soluble CD4 (sCD4) and bivalent CD4-Ig.
• To characterize the phenotypic changes in neutralization-resistant HIV-1 variants and understand which CD4 interaction aspects are dispensable for viral replication.

Main Methods:

• Selection of HIV-1 variants resistant to sCD4 and CD4-Ig under various conditions.
• Quantification of non-neutralized viral fractions after treatment with sCD4 or CD4-Ig.
• Assessment of viral sensitivity to neutralizing agents and characterization of gp120 affinity for CD4.
• Analysis of resistance using monoclonal antibodies targeting different CD4 domains (6H10 for domain 1, 5A8 for domain 2).

Main Results:

• HIV-1 isolates and clones developed resistance to sCD4 and CD4-Ig, with escape variants showing 2- to 100-fold reduced sensitivity.
• Selected variants exhibited decreased binding affinity of their gp120 to sCD4 and CD4-Ig.
• Monoclonal antibody 6H10, targeting the gp120-binding site in CD4 domain 1, was less effective against escape variants, suggesting altered domain 1 interactions.

Conclusions:

• HIV-1 can rapidly evolve resistance to sCD4 and CD4-Ig by modifying gp120 interactions with CD4.
• The escape variants display reduced attachment to cellular CD4, indicating that specific CD4 binding sites are less critical for viral entry.
• These findings highlight the adaptability of HIV-1 and have implications for the design of CD4-based entry inhibitors.